A company presented research detailing the observed effectiveness of a next-generation, blood-based colorectal cancer screening test at the annual United European Gastroenterology Week (UEGW) meeting in Barcelona, Spain. The presentation is the first set of data to support the clinical validity of this next-generation screening innovation. Specifically, the data demonstrate the performance of a circulating tumor DNA (ctDNA) blood test that detects three genes, BCAT1, IKZF1 & IRF4, that have been shown to be chemically modified, or hypermethylated, in colorectal cancer (CRC).
An estimated one-third of adults in the United States aged 50 to 74 years have not been screened for CRC. The main goal of this research is to validate a test that is both easier to prescribe for providers and easier to comply with for all patients. Samples used in this study were acquired…
